SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+9.08%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.47B
AUM Growth
+$1.47B
(-10%)
Cap. Flow
-$134M
Cap. Flow
% of AUM
-9.12%
Top 10 Holdings %
Top 10 Hldgs %
65.38%
Holding
60
New
12
Increased
13
Reduced
12
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$47.1M |
| 2 |
Intuitive Surgical
ISRG
|
$38.2M |
| 3 |
Biogen
BIIB
|
$36.9M |
| 4 |
Merck
MRK
|
$25.3M |
| 5 |
PTC Therapeutics
PTCT
|
$25M |
Top Sells
| 1 |
Sanofi
SNY
|
$95.2M |
| 2 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$74.6M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$54.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$45.3M |
| 5 |
AstraZeneca
AZN
|
$41.6M |
Sector Composition
| 1 | Healthcare | 99.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $322M | 20.6% | 1,773,124 -300,000 | -14% | -$54.5M |
|
2
Natera
NTRA
$23.1B
| $172M | 11.01% | 3,100,560 | – | – |
|
|
3
Merck
MRK
$210B
| $89.5M | 5.73% | 841,522 +238,166 | +39% | +$25.3M |
|
4
Ascendis Pharma
ASND
$11.8B
| $80.8M | 5.17% | 754,032 -126,768 | -14% | -$13.6M |
|
|
JBIO
5
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $75.8M | 4.85% | 3,758,686 | – | – |
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $57.1M | 3.65% | 627,683 -364,346 | -37% | -$33.1M |
|
|
7
Eli Lilly
LLY
$657B
| $47.1M | 3.01% | +137,100 | New | +$47.1M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $44.6M | 2.85% | 408,819 -4,354 | -1% | -$475K |
|
|
9
Intuitive Surgical
ISRG
$170B
| $38.2M | 2.44% | +149,589 | New | +$38.2M |
|
|
10
Biogen
BIIB
$19.4B
| $36.9M | 2.36% | +132,600 | New | +$36.9M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $34.9M | 2.23% | 359,035 -35,608 | -9% | -$3.46M |
|
12
DexCom
DXCM
$29.5B
| $29.9M | 1.91% | 257,227 +116,549 | +83% | +$13.5M |
|
13
Travere Therapeutics
TVTX
$1.56B
| $28.4M | 1.82% | 1,263,721 +685,453 | +119% | +$15.4M |
|
14
Vera Therapeutics
VERA
$1.38B
| $26.9M | 1.72% | 3,467,156 +285,714 | +9% | +$2.22M |
|
|
15
PTC Therapeutics
PTCT
$3.92B
| $25M | 1.6% | +517,095 | New | +$25M |
|
16
Zentalis Pharmaceuticals
ZNTL
$122M
| $24.8M | 1.58% | 1,439,062 +435,017 | +43% | +$7.48M |
|
|
INBX
17
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $23.5M | 1.5% | 1,244,488 +134,305 | +12% | +$2.53M |
|
|
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $23.2M | 1.48% | 1,002,348 +195,889 | +24% | +$4.53M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $22.7M | 1.45% | 1,075,424 +372,350 | +53% | +$7.86M |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $22M | 1.41% | 905,982 +267,584 | +42% | +$6.51M |
|
21
Immatics
IMTX
$619M
| $21.6M | 1.38% | 3,132,694 +1,131,918 | +57% | +$7.81M |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $20.9M | 1.34% | 3,655,308 | – | – |
|
23
Geron
GERN
$893M
| $18M | 1.15% | 8,274,892 +6,815,303 | +467% | +$14.8M |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $16.4M | 1.05% | 119,065 -128,890 | -52% | -$17.8M |
|
25
Exelixis
EXEL
$10.1B
| $16.1M | 1.03% | +831,243 | New | +$16.1M |
|